These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 19412810)

  • 21. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
    Desar IM; Mulder SF; Stillebroer AB; van Spronsen DJ; van der Graaf WT; Mulders PF; van Herpen CM
    Acta Oncol; 2009; 48(6):927-31. PubMed ID: 19452305
    [No Abstract]   [Full Text] [Related]  

  • 22. The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.
    Seandel M; Shia J; Linkov I; Maki RG; Antonescu CR; Dupont J
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6203-4. PubMed ID: 17062698
    [No Abstract]   [Full Text] [Related]  

  • 23. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
    Polyzos A
    J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):261-6. PubMed ID: 17945482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rare case of hemangiopericytoma responds to sunitinib.
    Mulamalla K; Truskinovsky AM; Dudek AZ
    Transl Res; 2008 Mar; 151(3):129-33. PubMed ID: 18279811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A differential response to sunitinib: sustained systemic response paralleled by intra-dural progression in the spine. Should standard response criteria be reviewed?
    Jafri M; Porfiri E
    Clin Genitourin Cancer; 2009 Aug; 7(2):E42-4. PubMed ID: 19692324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
    Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorafenib-associated remission of psoriasis in hypernephroma: case report.
    Fournier C; Tisman G
    Dermatol Online J; 2010 Feb; 16(2):17. PubMed ID: 20178713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A Case of Liver and Pulmonary Metastases from Adamantinoma, a Bone Tumor].
    Kurata T; Tajima H; Obatake Y; Nakanuma S; Makino I; Hayashi H; Nakagawara H; Miyashita T; Takamura H; Fushida S; Ota T
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1677-9. PubMed ID: 26805135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catching cancer by the tail: new perspectives on the use of kinase inhibitors.
    Khanna C; Gordon I
    Clin Cancer Res; 2009 Jun; 15(11):3645-7. PubMed ID: 19470723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dedifferentiated adamantinoma associated with fibrous dysplasia.
    Nouri H; Jaafoura H; Bouaziz M; Ouertatani M; Abid L; Meherzi MH; Ladeb MF; Mestiri M
    Orthop Traumatol Surg Res; 2011 Nov; 97(7):770-5. PubMed ID: 22000283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.
    Wolter P; Beuselinck B; Pans S; Schöffski P
    Acta Oncol; 2009; 48(4):621-4. PubMed ID: 19107622
    [No Abstract]   [Full Text] [Related]  

  • 32. Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh.
    Hanzer M; Nebl A; Spendel S; Pilhatsch A; Urban C; Benesch M
    Klin Padiatr; 2010 May; 222(3):184-6. PubMed ID: 20514624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term response with sunitinib for metastatic renal cell carcinoma.
    Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
    Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.
    Hu-Lowe D; Brega N; Patyna S
    Mol Cancer Ther; 2011 Nov; 10(11):2015. PubMed ID: 22072801
    [No Abstract]   [Full Text] [Related]  

  • 35. A case of progressive, metastatic adamantinoma in a pediatric patient.
    D'Souza AM; Bahrami A; Akeson J; Fahey T; Mitchell C; King R
    Pediatr Blood Cancer; 2021 Nov; 68(11):e29239. PubMed ID: 34264541
    [No Abstract]   [Full Text] [Related]  

  • 36. Spurious effects from an extraneous variable.
    Bross ID
    J Chronic Dis; 1966 Jun; 19(6):637-47. PubMed ID: 5966011
    [No Abstract]   [Full Text] [Related]  

  • 37. [M.B. Lund responds].
    Lund MB
    Tidsskr Nor Laegeforen; 2019 Nov; 139(16):. PubMed ID: 31686484
    [No Abstract]   [Full Text] [Related]  

  • 38. [T. Wisborg responds].
    Wisborg T
    Tidsskr Nor Laegeforen; 2019 May; 139(8):. PubMed ID: 31062568
    [No Abstract]   [Full Text] [Related]  

  • 39. [B. Bringedal responds].
    Bringedal B
    Tidsskr Nor Laegeforen; 2021 Feb; 141(3):. PubMed ID: 33624974
    [No Abstract]   [Full Text] [Related]  

  • 40. [A. B. Houge responds].
    Houge AB
    Tidsskr Nor Laegeforen; 2022 May; 142(8):. PubMed ID: 35635418
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.